ONCSQ (OncoSec Medical) ROE % Adjusted to Book Value: 0.00% (As of Jan. 2023)


What is OncoSec Medical ROE % Adjusted to Book Value?

OncoSec Medical ONCSQ -99.00% ROE % Adjusted to Book Value is 0.00% as of Jan. 2023.

OncoSec Medical's ROE % for the quarter that ended in Jan. 2023 was 0.00%. OncoSec Medical's PB Ratio for the quarter that ended in Jan. 2023 was N/A. OncoSec Medical's ROE % Adjusted to Book Value for the quarter that ended in Jan. 2023 was N/A.

OncoSec Medical ROE % Adjusted to Book Value Related Terms

OncoSec Medical ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for OncoSec Medical's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoSec Medical ROE % Adjusted to Book Value Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -80.56 -130.90 -31.74 -77.63 -33.34

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -88.16 -61.53 -70.80 0.00 0.00

ONCSQ vs NOVNQ, USRM, VRTX: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, OncoSec Medical's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoSec Medical ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's ROE % Adjusted to Book Value falls into.


OncoSec Medical ROE % Adjusted to Book Value Calculation

OncoSec Medical's ROE % Adjusted to Book Value for the fiscal year that ended in Jul. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-154.68% / 4.64
=-33.34%

OncoSec Medical's ROE % Adjusted to Book Value for the quarter that ended in Jan. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
OncoSec Medical (ONCSQ) has a ROE % Adjusted to Book Value of 0.00% as of Jan. 2023. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on OncoSec Medical and its competitors.
Is OncoSec Medical's ROE % Adjusted to Book Value too high?
OncoSec Medical's current ROE % Adjusted to Book Value is 0.00%.
How does OncoSec Medical's ROE % Adjusted to Book Value compare to NOVNQ and USRM?
OncoSec Medical's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on OncoSec Medical and its competitors. OncoSec Medical's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSec Medical stock overvalued right now?
OncoSec Medical (ONCSQ) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For OncoSec Medical (ONCSQ), the current ROE % Adjusted to Book Value is 0.00% as of Jan. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoSec Medical Business Description

Address 820 Bear Tavern Road, Ewing, NJ, USA, 08628-1021
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.